Technical analysis of None (QURE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.
Price Performance
| 1 month | -10.32% |
| 3 months | -8.21% |
| Year-to-date | +77.56% |
| 1 year | +200.07% |
| 3 years | +478.10% |
52-Week Range
| 52-week High | $71.50 |
| 52-week Low | $8.73 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $44.42 |
| SMA 200 | $28.92 |
| Beta | 0.75 |
| 30-day Volatility (annualised) | 40.1% |
| Price vs SMA 50 | -4.4% |
| Price vs SMA 200 | +46.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $67.69 | |
| 2025-11 | $27.51 | -59.4% |
| 2025-12 | $23.93 | -13.0% |
| 2026-01 | $22.72 | -5.1% |
| 2026-02 | $15.63 | -31.2% |
| 2026-03 | $16.35 | +4.6% |
| 2026-04 | $19.95 | +22.0% |
| 2026-05 | $28.53 | +43.0% |
| 2026-06 | $46.06 | +61.4% |
| 2026-07 | $43.63 | -5.3% |
| 2026-08 | $48.68 | +11.6% |
| 2026-09 | $42.49 | -12.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $0.21 | $63M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | $26M |
Price
| Price | $42.49 |
| Market Cap | $2.9B |